The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Gray Market Peptides: So Much Hype, So Little Data Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law